Bioequivalence and Bioavailability Forum 07:51 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Mithu
Junior

India,
2019-01-30 12:22
(edited by mittyri on 2019-01-30 12:52)

Posting: # 19828
Views: 207
 

 Two different lot of RLD in 2WC steady state study due to short shelf-life [Study Per­for­mance]

Dear Member

We are at the edge of start one of the injection study where we have to give six injections to subject in each period to achieve steady state. now each injection will be administer with the gap of 1 month. total duration of single period is around six month and same for the period II.

Now the actual challenge is, dosing date of each subject is different based on their availability and willingness to participate in the study. due to this reason, we are going to use two different lot of RLD in same study due to having very short self-life of RLD product.

My question is, how FDA will take this usage of 02 different lot of RLD in single study? do we need to normalize the data of all the subjects based on the differences of the RLD lot? does the usage of two different lot will be taken as treatment effect and will it be justified?

Regards,

Mithu


Edit: Category changed; see also this post #1. [Mittyri]
Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
19,187 posts in 4,084 threads, 1,308 registered users;
online 12 (1 registered, 11 guests [including 6 identified bots]).

In these days, a man who says a thing cannot be done
is quite apt to be interrupted by some idiot doing it.    Elbert Green Hubbard

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed